Fennec posts record FY2025 PEDMARK sales $44.6M (+50% YoY); Q4 $13.8M (+75%)

FENNEC PHARMACEUTICALS INC.

Full-year net product sales $44.6M vs $29.6M in 2024; Q4 $13.8M vs $7.9M in prior year.
Net loss $10.1M in FY2025 vs $0.4M in 2024, driven by higher G&A and a $2.0M loss on debt extinguishment.
Cash $36.7M at year-end; zero debt after paying down $21.5M term loan in Nov 2025.
Completed oversubscribed equity offerings raising $42.0M net; expanded commercial team.
Positive topline results from Japan trial; two institution-led studies initiated in testicular cancer and AYA patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.